Bank Julius Baer & Co. Ltd Zurich Decreases Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Bank Julius Baer & Co. Ltd Zurich trimmed its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 26.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,907 shares of the company’s stock after selling 691 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Intellia Therapeutics were worth $58,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in shares of Intellia Therapeutics by 7.3% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,651 shares of the company’s stock valued at $210,000 after buying an additional 451 shares in the last quarter. Victory Capital Management Inc. increased its stake in Intellia Therapeutics by 1.8% in the 3rd quarter. Victory Capital Management Inc. now owns 27,316 shares of the company’s stock worth $864,000 after purchasing an additional 470 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Intellia Therapeutics by 7.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 8,144 shares of the company’s stock worth $248,000 after purchasing an additional 582 shares during the period. Interchange Capital Partners LLC increased its stake in Intellia Therapeutics by 6.3% in the 4th quarter. Interchange Capital Partners LLC now owns 10,239 shares of the company’s stock worth $311,000 after purchasing an additional 605 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Intellia Therapeutics by 2.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,385 shares of the company’s stock worth $713,000 after purchasing an additional 647 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Trading Up 3.7 %

Shares of NTLA stock opened at $20.76 on Monday. Intellia Therapeutics, Inc. has a fifty-two week low of $19.37 and a fifty-two week high of $47.48. The business’s 50 day moving average price is $26.51 and its 200-day moving average price is $27.52.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. The company had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. During the same period in the previous year, the company posted ($1.40) earnings per share. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -5.57 earnings per share for the current fiscal year.

Insider Activity at Intellia Therapeutics

In related news, EVP James Basta sold 2,297 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $32.99, for a total transaction of $75,778.03. Following the sale, the executive vice president now directly owns 81,571 shares in the company, valued at $2,691,027.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Wedbush reaffirmed a “neutral” rating and issued a $29.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. The Goldman Sachs Group cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $136.00 to $32.00 in a research note on Friday, February 23rd. Canaccord Genuity Group lifted their price target on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Wolfe Research initiated coverage on Intellia Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $67.00.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.